anonymous
Guest
anonymous
Guest
That number seems really high given that nvs expects Kesimpta to be a billion dollar baby in 2-3 years. I’m hearing more like 20% or less. New territory alignments, potentially new abl, etc.
No way too low. They are cutting a lot to reinvest in virtual and other other platforms. Look at Pfizer they are doing the same. I would have a job lined up just in case. Plus unvaxed you will be first on the hit list.